2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-153839
    ODN 4084-F 1934318-44-1
    ODN 4084-F is a class B (‘broadly-active’) inhibitory ODN. ODN 4084-F is potent inhibitor of TLR9-induced B cells and macrophages.
    ODN 4084-F
  • HY-153841
    ODN INH-1 1934318-42-9
    ODN INH-1 is palindromic and a class R (‘restricted’) inhibitory ODN. ODN INH-1 is a potent inhibitor of TLR9-induced B cells and macrophages
    ODN INH-1
  • HY-153913
    MMP-9-IN-7 333746-76-2 98%
    MMP-9-IN-7 is a potent MMP9 inhibitor with an IC50 of 0.52 μM in proMMP9/MMP3 P126 activation assay. MMP-9-IN-7 is extracted from patent WO2012162468 (example 59), and can be used for MMP9/MMP13 mediated syndrome research.
    MMP-9-IN-7
  • HY-153930
    h15-LOX-2 inhibitor 1 478040-08-3 98%
    h15-LOX-2 inhibitor 1 (Comp 105) is a human epithelial 15-lipoxygenase-2 (h15-LOX-2) inhibitor with IC50 of 0.34 μM.
    h15-LOX-2 inhibitor 1
  • HY-153952
    Immuno modulator-1 2757469-20-6 98%
    Immuno modulator-1 (compound 22) inhibits TNFα and IL-2 secretion in human peripheral blood mononuclear cells (hPBMC), with IC50 values of 4.7 and 26 nM, respectively. Immuno modulator-1 shows hERG potassium channel blocking effect, with Inhibitory percentage of 20% at 3 μM.
    Immuno modulator-1
  • HY-153970
    URAT1 inhibitor 7 1632002-28-8 98.01%
    URAT1 inhibitor 7 (compound 10f) is a potent URAT1 inhibitor, with an IC50 of 12 nM. URAT1 inhibitor 7 exhibits microsomal stability (HLM <13 µL/min/mg). URAT1 inhibitor 7 also inhibits CYP2C9, with an IC50 of 4.2 μM. URAT1 inhibitor 7 can be used for gout research.
    URAT1 inhibitor 7
  • HY-153980
    K-80001 242800-40-4 98%
    K-80001 is an RXRα-binder and COX-1/2 inhibitor, with IC50s of with an IC50 of 82.9μM, 3.4μM, 1.2μM for RXRα, COX-1 and COX-2, respectively.
    K-80001
  • HY-154869
    PD-1/PD-L1-IN-34 2924403-17-6 98%
    PD-1/PD-L1-IN-34 (Compound (1S,2S)-A25) inhibits PD-1/PD-L1 interaction (IC50=0.029 μM), with a selected binding affinity with PD-L1 (KD=0.1554 μM). PD-1/PD-L1-IN-34 inhibits tumor growth by activating the immune microenvironment.
    PD-1/PD-L1-IN-34
  • HY-154916
    13-O-Desmethyl tacrolimus 139958-51-3 98%
    13-O-Desmethyl tacrolimus (13-DMT; 13-O-Demethyl FK 506) is the main metabolite of Tacrolimus (HY-13756). 13-O-Desmethyl tacrolimus has a weak immunosuppressive activity. 13-O-Desmethyl tacrolimus is mainly used in the research on monitoring Tacrolimus (HY-13756) by monitoring the ratio of 13-DMT/Tacrolimus.
    13-O-Desmethyl tacrolimus
  • HY-154979
    Anti-hepatic fibrosis agent 2 2380421-60-1 98%
    Anti-hepatic fibrosis agent 2 (Compound 6k) is an orally active COL1A1 inhibitor. Anti-hepatic fibrosis agent 2 is an anti-fibrogenic agent targeting ewing sarcoma breakpoint region 1 (EWSR1).
    Anti-hepatic fibrosis agent 2
  • HY-154994
    JAK-IN-30 2891469-99-9 98%
    JAK-IN-30 (compound 31) is a water-soluble JAK inhibitor with IC50 values of 2, 15, 18 and 2 nM for JAK2, JAK1, JAK3 and TYK2, respectively. JAK-IN-30 has research potential for dry eye disease (DED).
    JAK-IN-30
  • HY-155027
    DPP-4-IN-8 98%
    DPP-4-IN-8 (compound 27) is a potent and selective DPP4 (dipeptidyl peptidase 4) inhibitor, with a Ki of 0.96 μM. DPP-4-IN-8 blocks the dipeptidase activity of DPP4 in both Caco-2 and HepG-2 cells. DPP-4-IN-8 also dose-dependently suppresses the expression levels of the chemokines tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β).
    DPP-4-IN-8
  • HY-155029
    sEH inhibitor-16 2999636-75-6 98%
    sEH inhibitor-16 is a soluble epoxide hydrolase (sEH) inhibitors with an IC50 of 2 nM. sEH inhibitor-16 reduces the inflammatory damage in Cerulein (HY-A0190)-induced acute pancreatitis (AP) in mice and can be used for inflammation/immunology research.
    sEH inhibitor-16
  • HY-155031
    MCI 98%
    MCI alleviates inflammation by macrophage reprogramming via targeting ROS scavenging and COX-2 downregulation. MCI inhibits COX-2 with an IC50 value of 1.23 μM. MCI has significant anti-inflammatory effects in collagen-induced arthritis (CIA) models. MCI can be used in research for rheumatoid arthritis (RA).
    MCI
  • HY-155053
    ZIKV-IN-6 98%
    ZIKV-IN-6 (compound 22) is an inhibitor of Zika virus (ZIKV), with low cytotoxicity (CC50＞50 μM). ZIKV-IN-6 binds to ZIKV RdRp directly and inhibits viral RNA synthesis by ZIKV NS5. ZIKV-IN-6 suppresses the excessive inflammatory response and pyroptosis.
    ZIKV-IN-6
  • HY-155109
    Antitumor agent-114 2757762-91-5 98%
    Antitumor agent-114 is a potent stimulator of interferon genes (STING) agonist. Antitumor agent-114 activates immunity and reduces tumor volume in a mouse model of breast cancer. Antitumor agent-114 can be used for immunity and cancer diseases research.
    Antitumor agent-114
  • HY-155117
    MRS7925 98%
    MRS7925 (Compound 43) is a 5-HT2BR antagonist (Ki: 17 nM). MRS7925 can be used for research of fibrosis.
    MRS7925
  • HY-155123
    Antioxidant agent-13 2966778-87-8 98%
    Antioxidant agent-13 (Compound 5f) is an antioxidant agent. Antioxidant agent-13 inhibits DPPH and FRAP with IC50s of 80.33 and 85.69 μM. Antioxidant agent-13 also inhibits LOX and XO enzymes with IC50s of 16.85 and 23.01 μM.
    Antioxidant agent-13
  • HY-155132
    IRAK4-IN-28 2952532-92-0 98%
    IRAK4-IN-28 (compound 42) is an orally active IRAK4 inhibitor (IC50=8.9 nM). IRAK4-IN-28 has binding affinity for IRAK4 with a Kd of 0.58 nM. IRAK4-IN-28 can be used in the research of inflammation and autoimmune diseases.
    IRAK4-IN-28
  • HY-155133
    COX-2-IN-34 2788578-71-0 98.87%
    COX-2-IN-34 (compound 8a) is a selective and orally active inhibitor of COX-2 , with an IC50 of 0.42 μM. COX-2-IN-34 has no gastric ulcer toxicity but has anti-inflammatory effects.
    COX-2-IN-34
Cat. No. Product Name / Synonyms Application Reactivity